ITGAX and central nervous system cancer: Also in agreement with our analysis of CD8+ T-cell responses, CD11c-cre Kb cKO animals bearing GL261-quad gliomas displayed intermediate control of tumor burden, mirroring an intermediate immune response (Fig. 8a, b).